Sodium Zirconium Cyclosilicate Duration and Hyperkalemia-Related Healthcare Encounters in Patients with Heart Failure and Cardio/Renal Dysfunction: The GALVANIZE Outcome Study
Abstract Background and Objective Patients with heart failure or cardio/renal dysfunction (chronic kidney disease, end-stage kidney disease, or heart failure) are at increased risk of hyperkalemia. Sodium zirconium cyclosilicate (SZC) treats hyperkalemia, but the impact of SZC treatment duration on...
Na minha lista:
| Principais autores: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Adis, Springer Healthcare
2025-10-01
|
| Serier: | Drugs - Real World Outcomes |
| Online adgang: | https://doi.org/10.1007/s40801-025-00525-7 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|